Aerosol Delivery of CPZEN-45 for Treatment of Nontuberculous Mycobacterial (NTMs) Infections
Abstract
This DOD Therapeutic Development Award is focused on a new antibiotic, CPZEN-45, discovered by our team for treatment of non-tuberculous mycobacterial infections (NTM) in patients with chronic obstructive pulmonary disease (COPD). We have two major objectives: Objective 1 - To optimize fermentation and scale-up of manufacturing processes for high yield of CPZEN-45, including spray dried CPZEN-45. Objective 2 - To further define and characterize in vitro efficacy of CPZEN-45 against additional species of NTMs recently isolated from VA patients with COPD. Specifically, our objective is to develop an efficacious regimen for COPD patients by screening multiple CPZEN-45 combinations with standard NTM compounds in vitro and in vivo. The optimized synergistic regimens will then be tested in COPD mouse and guinea pig efficacy models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1201240
Entities
People
- Darrick Carter
- Gail Cassell